Barrington analyst Michael Petusky raised the firm’s price target on Haemonetics to $103 from $94 and keeps an Outperform rating on the shares following the fiscal Q3 beat. The company reported a strong Q3 and also significantly increased the lower end of its previously provided fiscal 2023 outlook, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HAE:
- Haemonetics price target raised to $115 from $110 at Mizuho
- Haemonetics raises FY23 adjusted EPS view to $2.90-$3.00 from $2.70-$3.00
- Haemonetics reports Q3 adjusted EPS 85c, consensus 80c
- Haemonetics 3rd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
- Haemonetics price target raised to $110 from $100 at Mizuho